131I-tositumomab 1770
3D reconstruction 1176
5-fluorouracil 1287, 1809
5-fluorouracil/leucovorin 1122
5-FU adjuvant chemotherapy 1833
5-FU/cisplatin 281
α5β1 integrin 1621
αvβ3 integrin 1621
A870D 928
AAV 1913
acidosis 884
acute childhood leukaemia 161
acute leukaemia 200
ADAM 724
ADAMTS 724
ADAMTS-8 1186
ADCC 259
adeno-associated virus 1913
adenocarcinoma 171, 896, 1460
adenomatous polyps 1718
adherence 507
adhesion 1311
adipocytokines 1221
adiponectin 156, 1221
adjuvant 492, 1122
adjuvant anthracyclines 1233
adjuvant therapy 30
adjuvant treatment 460
adoptive immunotherapy 1478
adrenomedullin 1
advanced and metastatic pancreatic cancer 481
advanced colorectal cancer 792, 964
advanced gastric cancer 959, 1130, 1803
aerobic glycolysis 578
aetiology 879
age and cancer 18
age at death 152
age-adjusted survival 446
ageing 593
AGR2 immunocytochemistry 1057
Akt 247, 398, 1906
albumin 227, 637, 1833
alcohol 757
ALL 1918
all-trans-retinoic acid (ATRA) 513
AML 323
AMN107 1765
anaemia 947
aneuploidy 891
aneusomy 891
anger 1245
angiogenesis 1, 101, 524, 552, 654, 1176, 1186, 1300, 1621, 1650
angiogenic factors 524
angiostatic 1845
angiotensin II 552
anthracycline pretreated 1615
antidepressant agents 1071
antihypertensive drugs 752
antiproteolytic drug 941
antithrombotic prophylaxis 189
antitumour immunity 391
anxiety 1093, 1253
apoptosis 13, 108, 253, 776, 1412, 1436, 1592
arachidonic acid 842
ARF 1555
ARF-BP1 1555
aromatase inhibitors 460, 1051, 1789
array CGH 1927
arsenic trioxide 398
AT1 receptor 552
ATM gene 1537
ATN-161 1621
audit 486
autoantibodies 1066
autocrine loop 1180
Axl 1446
azolyl retinoids 513
β-catenin 686, 1672
basal-cell carcinoma 743
basic anticancer drugs 863
BCR-ABL 1765
behavioural problems 43
benzoporphyrin derivative 391
bevacizumab 614
bexarotene 654
bFGF 1627
biliary disease 1751
bioactivation 1226
biochemical changes 1460
biomarkers 717, 1087, 1420, 1592, 1898
birth cohort 152
birth outcome 142
birth weight 1734, 1738
bladder cancer 1465, 1703
blood vessel density 1580
blood vessel invasion 1643
BMP-2 436
BMS-188797 79
body height 740
body mass index 740
bone loss 30
bone marrow 842
bone resorption 1496
borderline ovarian tumour 1586
boric acid 884
Borrelia burgdorferi 879
brain metastases 1777
brain tumours 1186, 1428
BRCA 814
BRCA1 308, 407
BRCA2 407
breast 253, 1333
breast cancer 8, 13, 30, 36, 43, 142, 152, 231, 239, 247, 299, 308, 333, 346, 358, 460, 469, 473, 524, 532, 540, 548, 672, 828, 1051, 1071, 1144, 1154, 1237, 1245, 1492, 1610, 1615, 1637, 1643, 1697, 1734, 1745, 1777, 1874, 1921
breast cancer risk 1537
breast cancer screening 147
breast cancer survival 147
breast epithelium 1021
breast neoplasms 427, 681
cachexia 731
CAEBV infection 599
CAM5.2 293
cancer distress 507
cancer genome 1927
cancer mortality 1079
cancer pain 1559
cancer stem cells 710
cancer survival 446
cancer therapy 941
cancer-specific survival 781
cancer/testis antigen 710, 1864
capecitabine 74, 959, 964, 969, 976, 1122, 1281, 1407
carboplatin 55, 62, 74, 1267, 1580
carcinoma 1472
cardiac toxicity 1016
case–case–control 743
case-control studies 752, 1071
catabolism 513
CCI-779 614
CCND1 928
CCNL1 1041
CD13 1627
CD4 cell counts 1000
CD4+ T cells 275
CD8+ T cells 275
cell cycle 93, 1045
cell cycle arrest 532
cell cycle control 184
cellular proliferation 776
central venous catheters 189, 200
cervical cancer 1045, 1683, 1913
cervical intraepithelial neoplasia 1253
cervical neoplasms 171, 1678
cervix 115, 1690
cetuximab 792
CGH 333
chemobyl 1472
chemokines 1029
chemoprevention 407
chemoradiation 363
chemoradiotherapy 351, 1375, 1389
chemosensitivity 203
chemotherapy 18, 51, 427, 524, 692, 785, 828, 1011, 1087, 1267, 1369, 1389, 1407, 1572, 1837
chemotherapy activity 1099
childhood leukaemia 156, 763, 1342
chloroquine 863
CHOP 806
chromatin 179
chromosomal damage 308
chromosome 11q23.2 1524
chromosome 3q 1041
chromosome instability 1485
circulating DNA 1492
circulating endothelial cells 524
circulating tumour cells 8
circumferential resection margin 351
cisplatin 79, 1375
c-jun N-terminal kinase 532
c-kit 1874
CKMT1 698
CL 1
clear cell 642
clear cell carcinoma 1369
clinical response 1051
clinical trial 609, 1136, 1237, 1267, 1420, 1803
c-MYC 1658
cognitive dysfunction 828
cohort study 142, 171, 1339, 1533
collagen XVIII 1066
colorectal adenoma 928
colorectal cancer 69, 128, 311, 586, 798, 928, 1116, 1122, 1136, 1287, 1300, 1320, 1412, 1478, 1672, 1710, 1816, 1823, 1833, 1898
colorectal carcinogenesis 922, 1718
colorectal liver metastases 982
colorectal polyp 311
combination chemotherapy 1130, 1287
combination effects 1837
combination therapy 69, 1604
combined modality treatment 1389
communication 208
concurrent radiotherapy 625
concurrent therapy 1375
conditionally replicative adenovirus 1837
conjunctiva squamous cell carcinoma 450
conjunctival intraepithelial neoplasia 450
conservative surgery 1586
continual reassessment method 609
contrast enhancement 427
correlation 1226
correlative markers 1136
cost-effectiveness 492, 1122
country of birth 1079
COX-2 1154, 1300
C-reactive protein 227, 1568, 1833
CRLR 1
cutaneous T-cell lymphoma 879
CXCL6 1936
CXCR1 1936
CXCR2 1936
cyclin A 1697
cyclin D 928
cyclin E 1045
cyclin L1 1041
cyclo-oxygenase (COX) 253, 346
cyclooxygenase-2 1718
cyclophosphamide 1226
CYP26 513
cystectomy 1586
cystoplasty 891
cytokeratin-19 672, 1164
cytokines 1412
cytology 1170, 1690
D2-40 293, 1643
dairy fat 165
dairy products 165
dasatinib 1765
database 318
dbpC/contrin 710
DCE–MRI 1420
DCIS 253
DDD 1204
delay 955, 1272
denaturing HPLC 268
denial (minimising) 1245
depressed neoplasia 311
depression 372
depressive disorder 1093
dermcidin 1663
dexamethasone 1011
diagnosis 904, 1272
diagnostics 1492
differential diagnosis 1726
differentiation 1637
diffusion study 427
disseminated epithelial cells 672
DJ-1 620
DNA damage 1194, 1942
DNA deletion 1887
DNA methylation 179, 1087
DNA quantification 1492
DNA repair 1194
DNA-PK 1683
DNMT3b 593
docetaxel 55, 62, 1233, 1375, 1402, 1803
dorsal skinfold chamber model 101
dose dense 1237
dose escalation 609
dose-finding studies 609
downstaging 1099
doxorubicin 1797
DR5 398
drug design 941
drug resistance 1087
DU-145 884
Dukes stage 1833
dynamic contrast-enhanced magnetic resonance imaging 1420
dysplasia 1170
EBV DNA microarray 599
E-cadherin 661, 1326, 1816
education 152
efaproxiral 1777
EGFR 85, 771, 896, 1136, 1144, 1703
EGGCT 820
eIF4E binding proteins 195
eIF4F 195
elderly 806, 969
electromagnetic fields 161
EMD 72000 1293
emotional problems 43
EMR 407
endocrine therapy 30, 828, 1789
endoplasmic reticulum stress response 407
endosomal pH 863
endostatin 1066
endothelial cells 1, 1428, 1845
England and Wales 1079
EP receptors 1154
Ep-CAM 128
epidemiology 142, 171, 737, 1533, 1690, 1751
epidermal growth factor 1703
epidermal growth factor receptor 184, 1293
epigenetics 179, 914, 1087
epirubicin 74, 1233, 1237, 1263, 1572
epithelial–mesenchymal transition 661
epoetin alfa 947
Epstein–Barr virus 599, 1504
ERα 593
ERα-positive breast cancer 1057
ERβ varient 1333
ErbB 1703
erbB2 247
erlotinib 614, 1136
esophageal cancer 1281
estimated dose 1342
etoposide 1263
Ewing's sarcoma 22
exposure 1226
expressed emotion 1245
extracellular matrix 1311
extragonadal germ cell cancer 820
family health 499
family history 231
Fas-associated death domain 532
fertility 1007
FFPE archive 333
FGFR4 Arg388 polymorphism 1879
FGFR4 protein expression 1879
fibronectin 1311
fibrosarcoma cells 854
filgrastim 1237
first-line 959, 1789
FISH 1452, 1472
flat adenomaBRAF mutation 311
FLIP 398
fluorescence imaging 391
fluorescence in-situ hybridisation 891
fluorouracil 1107
folate 964
FOLFOXIRI 798
folic acid 1942
fractional polynomials 1785
FRAT1 686
frizzled related protein 922
fulvestrant 1021
GAGE 1864
G-CSF 806
gastric cancer 136, 281, 1204, 1281, 1402, 1407
gastrin 1107
gastrointestinal tumour 1180
gastro-oesophageal cancer 637, 1568
GCP-2 1936
gefitinib 85, 631, 1599
gelatinases 1035
gemcitabine 62, 1293, 1572, 1575, 1797
gemcitabine plus oxaliplatin 481
gemcitabine triphosphate 1797
gene expression 121
gene expression analysis 1927
general practice 1116
genetic polymorphism 203
genistein 407
germ cell tumours 1231
gestational trophoblastic disease 51
glioblastoma multiform 108
glioma 752, 1186, 1853
glutathione S-transferase P1 281
grade 781
GRAF 323
green fluorescent protein 391
Groucho/TLE 771
growth arrest 1637
growth regulatory gene 1524
GSTP1 473
HAART 1000
haemoglobin 947
haplotypes 1537
HCC 737
HCT116 1326
HCV 737
head and neck 1041
head and neck cancer 631, 647, 692, 955, 1516
head and neck squamous cell carcinoma 1164
health 1942
hepatocellular carcinoma 287
HER 1703
HER2 85, 1144
HER3 1144
hereditary cancer 814
high response 1575
high-dose chemotherapy 1016
high-risk populations 1537
histamine dihydrochloride, oxidative stress 218
histone deacetylase inhibitor 1436
histones 179
HIV 1000
hnRNP K protein 586
HNSCC 1041
Hodgkin's lymphoma 469, 1007
homologous recombination 1326
hormone replacement therapy 136
hPTTG1 1672
HPV 1913
hTERT 870, 1452
human immunodeficiency virus 450, 1504
human kallikrein 14 540
human papillomavirus 171, 1690, 1913
human pituitary tumour transforming gene 1672
human tumour specimens 1516
hypoxia 115, 121
hypoxia-inducible factor 115
IGFALS 299
IGFBP-1 299
IGFBP-3 299
IGF-I 299
imatinib-resistance 1765
immune suppression 1412
immunohistochemistry 108, 275, 532, 540, 710, 904, 1678, 1864, 1894, 1906
immunoprecipitation 548
immunotherapy 1029, 1785, 1864
in utero exposure 1734
incidence 1342, 1751
indole-3-carbinol (I3C) 407
inducible nitric oxide synthase 184
infant 1510
inflammation 731, 1465
inflammation-mediated tumour progression 854
inhibitors 513, 1355
insulin resistance 1221
insulin-like growth factor receptors 465
insulin-like growth factors 465
interferon 1465
interferon-alpha 492
interferon-γ 1845
interleukin-2 218
invasion 1186, 1627
invasiveness 1428
investigations 1116
involved field 625
IRESSA 1599
irinotecan 55, 792, 976, 1130, 1267, 1281, 1287, 1402, 1407
irradiation 308
ISG15 1465
isolated tumour cells 293
JACC study 737
Japanese 737
Jewish breast cancer patients 1537
kallikrein 540
Kaposi's sarcoma 1000, 1504
Kaposi's sarcoma-associated herpesvirus 1504
keratinocytes 85
K-ras 896
lactose 165
laminin 1311
laparoscopic ultrasound 213
laparoscopy 213
laser capture microdissection 569, 1452
late effects 469
late recurrence 820
late relapse 820
LDH 1231
leucovorin 1287
leukaemia 156, 161, 398, 1738, 1918
limited stage 625
liposomal doxorubicin 1615
liver 1663
liver disease 1751
longitudinal studies 1093
long-term follow-up 1770
long-term survivor 1099
loss of heterozygosity (LOH) 1485
lung 724
lung cancer 18, 128, 896, 1029, 1176, 1485, 1936
lung metastasis 51
lyme disease 879
lymph node metastasis 1369
lymph nodes 1164
lymph vessel invasion 1643
lymphangiogenesis 1154, 1650
lymphatic density 1650
lymphatic vessel 1355
lymphoblastic leukaemia 161
M30-ELISA 1592
macrophage 101
MAGE-A1 1864
magnetic resonance 427
magnetic resonance imaging 351
MALDI-TOF-mass spectrometry 698
malignancy 189
malignant spinal cord compression 486
malignant transformation 195
mammaglobin 672, 681
mammary cell lines 661
mantle radiotherapy 469
MAPK pathways 311
mass screening 499, 1253, 1510
mass spectrometry 1898
maternal age 1738
maternal weight 1738
mathematical model 93
matuzumab 1293
maximum tolerated dose 609
MCF-7 1637
MDA-MB-231 1637
Mdm2 1555, 1683
MDR1 473
MDS 323
melanoma 492, 743, 835, 1496, 1627, 1879
menstrual cycle 1690
mercaptopurine 93
mesothelin 436
metallothionein 835
metastasis 13, 654, 785, 798, 842, 854, 1936
metastatic breast cancer 227, 1016, 1233, 1604, 1789
metastatic colorectal cancer 969
metastatic pancreatic cancer 1575
methodology 1559
methylation 561, 914
methylation-specific PCR 1492
M-FISH 308
microarray 436, 904
micrometastasis 293, 681, 1164
microRNAs 776
microsatellite instability 1485
microvessel density 1823, 1879
migration 884, 1311
milk 165
minichromosome maintenance proteins 1170
minisatellite instability 1485
mitochondrial DNA 692, 1887
mitochondrial DNA mutations 268
mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes 268
MMP 569
MMP-7 1035
MMP-8 1035
MMP-9 1035
MoA 259
models of viral transmission 1533
modified nucleosides 1726
monoclonal antibodies 128, 465
Moran's I 763
mouse mammary tumour virus (MMTV) 548
mouth neoplasm 647
MR 427
MRP1 473
mTOR 195
mucinous 904
multidisciplinary team 351
multiple primary cancers 1745
multivariate analysis 1586, 1853
mutation 318, 692, 896, 1918
MYCN 1510
mycosis fungoides 879
Myeov 1204
MYOD 593
naive patients 1000
nasal NK/T-cell lymphoma 599
nausea 1011
neck dissection 1164
neoadjuvant chemoradiotherapy 976
neoadjuvant chemotherapy 358, 363
neoadjuvant therapy 1051
nephrectomy 781
Net1 1204
neuroblastoma 13, 1510, 1845
NF-κB 1436
nilotinib 1765
non-Hodgkin's lymphoma 806, 1339, 1504, 1770
non-seminoma 820
non-small-cell lung cancer 275, 1375, 1383, 1599, 1927
Notch 771
novel gene 1524
NSAIDS 346
nuclear sites 1342
nucleostemin 1658
NY-BR-1 681
obesity 1221
oesophageal adenocarcinoma 136
oesophageal carcinoma 1389
oesophagus 203, 1460
oestradiol 1021
oestrogen receptor 1333
oestrogens 136, 1734
Omega 3 842
Omega 6 842
omeprazole 863
oncogene 776
opioids 1559
oral cavity 1170
oral cavity cancers 1580
oral squamous cell carcinoma 561, 698, 717
orally available superoxide dismutase 854
osteoclast 1496
osteosarcoma 22, 1837
outcomes 36, 1361
ovarian cancer 62, 74, 436, 552, 686, 757, 814, 904, 914, 1650
ovarian cryopreservation 1007
ovarian neoplasms 165
ovary 55, 947, 1369
oxaliplatin 69, 785, 959, 969, 1809
oxidative phosphorylation 268
p110α 455
p21 1683
p300 1326
p53 1555, 1683
paclitaxel 1237, 1263, 1369, 1894
pAKT 1678
palliation 631
pancreatic cancer 213, 785, 1107, 1293, 1572
papillary 1472
papillary serous 642
papillomavirus 450
Parkinson's disease 620
Parthenolide 1436
pathological complete response 358
patient survival 1057
patterns of care 22
pentose phosphate pathway (PPP) 578
performance status 781
peripheral blood lymphocytes 1194
pertuzumab 85
PG-dependent gene expression 1718
pharmacodiagnostic marker 578
pharmacoeconomics 1122
pharmaco-epidemiology 752
pharmacogenetics 281
pharmacological interventions 372
phase 1 trial 609, 1621
phase I/II 1803
phase II study 792, 1136, 1287, 1383, 1395, 1575
phosphorylation 532, 586, 870
photodynamic therapy 391
physician-patient relations 208
PI3K 455, 1678
PIK3CA 455
PKC isoenzymes 870
placebo 1107
PMitCEBO 806
Poly(A) binding protein- interacting protein 2 1516
poly(ADP-ribosyl)ation 341
polymerase chain reaction 879
polymorphism 593, 928
pooled analysis 757, 1789
poor prognosis 717
population-based 231
population-based study 1339
postmenopausal 1789
postmenopausal hormone replacement therapy 1339
Potthoff–Whittinghill method 763
pregnancy weight gain 1738
preoperative radiotherapy 1809
primary cell cultures 1837
primary systemic therapy 259
prognosis 8, 208, 358, 473, 552, 692, 731, 1785, 1816, 1874, 1906
prognostic factors 275, 835, 1823
prognostic marker 540
prognostic score 227
prognostic value 1516
proliferation 1021, 1051, 1412
promoter methylation 323, 593, 661
prophylactic surgery 814
prospective study 740
prostaglandins 346, 1718
prostate cancer 128, 507, 740, 842, 884, 1361, 1592, 1906
prostate-specific antigen 499
prostatic neoplasms 499, 1093
protein kinase C 1436
proteinases 724
proteome 287
proteomics 717, 1853, 1898
PSA recurrence 1906
psychological factors 1253
psychological morbidity 507
psychotherapeutic interventions 372
PTEN 247, 620
PU.1 1918
pyrosequencing 561
QC 333
QPCR 1452
quality of life 492, 947, 1093, 1116
quantitative RT–PCR 569
questionnaires 1253
radiation resistance 1678
radiation sensitiser 1777
radiation therapy 1375, 1580
radiation-induced fibrosarcoma 391
radioimmunotherapy 1770
radiosensitivity 1683
raltitrexed 785, 1809
Raman spectroscopy 1460
RAMBAs 513
randomised trials 1233
RANKL 1496
rapamycin 195
rat 1853
RB1 1921
RCC 1658
real-time PCR 731, 1164, 1887
receptor tyrosine kinase 184, 1446
rectal cancer 351, 363, 976, 1809
recurrence 253
referral 955
relapse 74, 1231
renal cell carcinoma 218, 268, 781, 1217, 1785
renal tissues 1658
repression 1245
resection 1568
residual ductal carcinoma in situ (DCIS) 358
residual invasive carcinoma 358
retinoid X receptor 654
retroperitoneal lymph node dissection 820
risk 752, 1339, 1785
RNA editing 586
RNA Interference 1300
RSR13 1777
RT–PCR 473, 672, 681
S-1 1130, 1575, 1803
safety 964
salvage therapy 785
sarcoma 1180
scan statistic 763
SCF 1180
SCLC 625, 1263
screening 507, 896, 1093, 1170, 1690
screening as independent prognostic factor 147
second line chemotherapy 481
SEER 1745
SELDI 287, 1853, 1898
selective COX-2 inhibitor 346
seminoma 820
senescence 884
sentinel node 1478
sequencing schedules 460
sequential therapy 62
serine protease 540
seroprevalence 548
serous tumour 1586
serum 287
serum proteome 1898
side effects 1011
signal transduction 771
single nucleotide polymorphisms 299, 921
single-cell gel electrophoresis 1194
skin cancer 743, 1446, 1887
skin rash 85
Slug 1816
small-cell lung cancer 1267, 1927
small-molecule EGFR tyrosine kinase inhibitors 1604
smoking 896
SNP 1537
soft tissue sarcoma 1797
somatic 318
somatic mutations 455
sorafenib 614, 1217
space–time analyses 763
sparse data 446
spatial heterogeneity 763
specialisation 36
spectroscopy 427
squamous cell carcinoma 171, 203, 743, 1041, 1170
Src kinase 1710
stage IIIA NSCLC 1099
staging 213
stathmin 717
Staurosporine 1436
steroid receptors 1021, 1051
stomach cancer 128
sun exposure 743
sunitinib 614, 1217
surgery 982, 1116
surveillance 814, 1231
survival 22, 36, 227, 231, 239, 637, 642, 647, 982, 1245, 1412, 1568, 1663, 1823, 1833, 1879
survival analysis 208
survivin 108, 253
susceptibility to chemotherapy 1894
systematic review 372, 982, 1272, 1559
systemic inflammatory response 227, 781
tamoxifen 1021
tankyrase 341
target validation 941
targeted intra-arterial chemotherapy 1580
targeted therapy 1144
tau 1894
taxanes 55, 79, 1375, 1604
telomerase 341, 870, 1452
telomeres 341
testicular cancer 820
testis 1864
TFGβ pathway 661
therapeutic monitoring 8
thrombomodulin 1320
thrombosis 189
thymidine phosphorylase 115
thymidylate synthase 121, 281
thyroid 1472
time trends 152
TIMP 1035
tissue inhibitor of metalloproteinases 1035
tissue microarray 686, 1697
tissue penetration 863
tissue remodelling 1428
TNM stage 1568
TNM stage C-reactive protein 637
tobacco 692
toxicity 609
trabectedin 1610
TRAIL 398
transcription factor 1918
transcriptional regulation 184, 771
transfection 698
transforming growth factor-beta1 239
transfusion 647
transitional cell carcinoma (TCC) of the bladder 1395
transketolase (TKT) 578
transketolase-like-1 (TKTL1) 578
translational control 195
trastuzumab 247, 259, 1016, 1144
treatment 231, 1592
triple-agent therapy 62
truth disclosure 208
tumour 1, 1472, 1845
tumour budding 293
tumour marker 8, 1726
tumour reactive lymphocytes 1478
tumour regression grade (TRG) 1809
tumour stage 781
tumour suppression 620
tumour suppressor 776
tumour thickness 1879
twist-1 13
two-dimensional electrophoresis 698
tyrosine kinase inhibitors 465
ubiquitin-like protein 1465
UCN-01 1436
UFT® 69
Uganda 450
ultraviolet radiation 1887
upper gastrointestinal 1272
uracil misincorporation 1942
urine 1726
urothelial cancer 569
uterine 642
valproic acid 1436
vascular density 1650
vascular endothelial growth factor (VEGF) 101, 552, 724, 1217, 1710
vascular endothelial growth factor-A 1516
VEGF expression 1823
VEGF-C 1154, 1355
VEGF-D 1355
VEGFR-1 1710
VEGFR-3 1355
veno-occlusive disease 1226
venous thromboembolisms 200
vinflunine 1383, 1395
viral load 1000
virotherapy 1837
vomiting 1011
von Hippel–Lindau 614
Warburg effect 578
WEB-2086 1637
Western immunoblot 548
whole-brain radiation therapy 1777
Wilms tumour 1524
Wnt pathway 686
Wnt-signalling 922, 1672
XELOX 969
Yondelis 1610
zinc chelation 941
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 94. Br J Cancer 94, 1960–1963 (2006). https://doi.org/10.1038/sj.bjc.6603218
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6603218